Interestingly, in a phase 2 study in patients with uncontrolled asthma, the H4R antagonist toreforant displayed significant improvements in a pre-specified subgroup, which displayed sputum eosinophils or blood eosinophils at baseline [36]. The gene discussed is HRH4; the disease is asthma.